Analysts expect $21.8b 2012 Teva revenue

Teva will announce its 2012 business outlook at a live webcast next Wednesday.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) today announced that it will host a conference call and live webcast on Wednesday, December 21, 2011 at 8:30 am EST to communicate its 2012 business outlook, followed by a question and answer session. The company did not provide any further details.

The analysts full-year 2012 consensus is $5.67 earnings per share on $21.8 billion revenue. Their fourth quarter 2011 consensus is $1.57 earnings per share on $5.57 billion revenue, and the full-year consensus is $4.95 earnings per share on $18.3 billion revenue.

Factors that will strongly affect Teva's results for the fourth quarter of 2011 and first half of 2012 include a launch of a generic version of Pfizer Inc. (NYSE: PFE; LSE: PFZ) anti-cholesterol drug Lipitor.

Teva's share price has fallen 24% this year, although it has risen 6.5% in the past three months. The share price fell 1% in early trading on the TASE today to NIS 152.90, after rising 0.1% on Nasdaq yesterday to $40.90, giving a market cap of $36 billion.

Published by Globes [online], Israel business news - - on December 14, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018